

Erectile dysfunction treatments other than pharmaceuticals

Clinical Policy ID: CCP.1433

Recent review date: 12/2025

Next review date: 4/2027

Policy contains: surgical revascularization; penile vacuum pump; erectile dysfunction; impotence.

FirstChoice VIP Care has developed clinical policies to assist with making coverage determinations. FirstChoice VIP Care's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered, on a case by case basis, by FirstChoice VIP Care when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. FirstChoice VIP Care's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. FirstChoice VIP Care's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, FirstChoice VIP Care will update its clinical policies as necessary. FirstChoice VIP Care's clinical policies are not guarantees of payment.

Coverage policy

Vacuum erection devices and penile arterial reconstruction are clinically proven and, therefore, may be medically necessary when the following criteria are met (Burnett, 2018):

- The member is diagnosed with erectile dysfunction.
- Conservative treatments have been attempted for at least 12 months and have failed.

Note: This policy does not address penile prosthesis implants.

Limitations

Other non-pharmaceutical interventions for erectile dysfunction are investigational/not clinically proven, and therefore, not medically necessary — including venous surgery, low-intensity extracorporeal shock wave therapy, intra-cavernosal stem cell therapy, and platelet-rich plasma therapy (Burnett, 2018).

Alternative covered services

Various medications (not addressed in this policy).

Background

Erectile dysfunction, also referred to as impotence, is defined as the inability to achieve or maintain an erection that is sufficient for satisfactory sexual performance. Some form of erectile dysfunction will affect 40% of men in their 40s; 50% of men in their 50s; 60% of men in their 60s; and higher rates for men over 70 (Ferrini, 2017).

Erectile dysfunction was once believed to be a psychological disease, but more than 80% of cases are now considered to have an organic etiology. Conditions associated with the disorder include hypogonadism, lower urinary tract symptoms, benign prostatic hypertrophy, hypertension, cardiovascular disorder, smoking, excess alcohol intake, obesity, dyslipidemia, diabetes mellitus, metabolic syndrome, stress, anxiety, and depression. Reactions to various surgeries and medications can also cause erectile dysfunction (Yafi, 2016).

Erectile dysfunction is a highly under-treated condition. A study of 6.2 million males diagnosed with erectile dysfunction found that only 25.4% were treated (at least one filled prescription for phosphodiesterase type 5 inhibitor, injection or urethral prostaglandins, or androgen replacement) over a 12-month period. Men older than age 60 were significantly less likely ($P < .0001$) to be treated than males ages 40 to 59 years (Frederick, 2014).

Conservative treatment options consist of lifestyle changes, psychosexual therapy, oral phosphodiesterase type 5 inhibitors, and prostaglandin E1 intracavernous injections. When conservative treatments cannot be tolerated or do not result in improvements, erectile dysfunction can be treated using non-invasive and invasive approaches. A vacuum erection device is an acrylic cylinder with a pump attached directly to the end of the penis, and a constriction ring or band is placed on the cylinder at the other end, which is applied to the body. The cylinder and pump create a vacuum to help the penis become erect, while the band or constriction ring helps maintain the erection (Shindel, 2022).

Surgical options include penile arterial reconstruction and penile prosthesis placement, which has replaced venous surgery as the recommended standard of care. Penile arterial reconstruction can improve blood flow to the penis. It is generally reserved for select patients, such as healthy young men with either congenital or traumatic erectile dysfunction, not with arteriosclerosis as a cause (Shindel, 2022).

Findings

Guidelines

The American Urological Association guideline on erectile dysfunction recommended six types of treatments. Three are medications, while the others include vacuum erection devices and penile arterial reconstruction — for both, the guideline states that patients must be informed of potential risks and benefits before treatment starts. Penile arterial reconstruction may be considered for young men with erectile dysfunction and focal pelvic/penile arterial occlusion and without documented generalized vascular disease or veno-occlusive dysfunction. A vacuum erection device may be an option. Treatments not recommended are venous surgery, low-intensity extracorporeal shock wave therapy, intracavernosal stem cell therapy, and platelet-rich plasma therapy (Burnett, 2018).

The Canadian Urological Association agreed that oral medications should be first-line therapy. However, second-line therapies and surgery are also important options in treating confirmed cases of erectile dysfunction (Bella, 2015). The British Society for Sexual Medicine guideline supported use of vacuum erection devices but did not mention penile arterial reconstruction (Hackett, 2018).

The American Academy of Family Physicians guideline recommended lifestyle changes (including tobacco cessation, exercise, weight loss, control of diabetes, hypertension, and hyperlipidemia), plus oral phosphodiesterase-5 inhibitors as first-line treatments for erectile dysfunction. The Academy recommended

alprostadil and vacuum devices for second-line therapy, and surgically implanted penile prostheses when other treatments have failed (Rew, 2016).

The American Society of Clinical Oncology endorsed a guideline, including a recommendation that people with cancer be counseled about sexual health and dysfunction related to cancer. The guideline states that if medical management does not succeed, medication such as phosphodiesterase type 5 inhibitors may be beneficial, and surgery remains an option for males with erectile dysfunction (Carter, 2018).

The 2025 European Association of Urology guideline on sexual and reproductive health reiterated that vacuum erection devices are an established noninvasive option with high short-term success and moderate long-term adherence, particularly suitable for older men with comorbidities who prefer drug free treatment. The guideline restricts penile arterial reconstruction to carefully selected young men with posttraumatic focal arterial lesions and intact veno-occlusive function. It does not recommend venous ligation surgery because of poor long-term outcomes. Low-intensity extracorporeal shock wave therapy and platelet-rich plasma injections are described as promising but experimental regenerative modalities, with modest short-term improvements in erectile function and low overall certainty of evidence. Both are recommended only in research settings. Intracavernosal stem cell therapies are considered early-phase investigational interventions without sufficient efficacy data for routine clinical use (European Association of Urology, 2025).

The Sexual Medicine Society of North America position statement on restorative therapies for erectile dysfunction evaluates low-intensity extracorporeal shock wave therapy, platelet-rich plasma injections, and stem cell-based therapies. It concludes that current clinical data are limited, and heterogeneous, robust evidence of efficacy is lacking, and these restorative modalities should be confined to clinical trials rather than routine practice (Liu, 2021).

Evidence reviews

A number of systematic reviews or meta-analyses and other large-scale studies have appeared in the professional literature addressing safety and effectiveness of various treatments for erectile dysfunction.

Vacuum erection devices

- A systematic scoping review of 16 studies, including seven randomized controlled trials, documented improvements after vacuum erection, both with and without phosphodiesterase type 5 inhibitors, in International Index of Erectile Function scores, conservation of penile length, and satisfactory intercourse (Pirola, 2024).
- A systematic review/network meta-analysis of 24 randomized trials ($n = 3,500$) of males with erectile dysfunction after prostatectomy found vacuum constriction devices (four trials) were the most effective intervention in improving erectile function scores three months of surgery. Devices improved outcomes when added to drugs, but there was no improvement when medication was added to vacuum device monotherapy (Feng, 2021).
- A systematic review and meta-analysis of clinical studies of vacuum erection devices found that vacuum devices produced significantly greater improvements in International Index of Erectile Function scores than placebo or no treatment (mean difference about 4 points) and similar erectile function outcomes compared with phosphodiesterase type 5 inhibitor monotherapy; combination therapy with vacuum devices plus phosphodiesterase type 5 inhibitors yielded greater improvements than drug therapy alone (Theodorus, 2025).

Penile arterial reconstruction

- A systematic review and meta-analysis of 16 articles (n = 374) assessed efficacy and safety of endovascular therapy in patients with veno-occlusive dysfunction or arterial insufficiency. Overall clinical success rates for the groups were 59.8% and 63.2%; complications occurred in 5.2% and 4.9% (Doppalapudi, 2019).
- A study of 110 patients tracked an average of 73.2 months after penile revascularization surgery showed an increase in erection function from 7.3 to 16.8 points. The three-month success rate (> 5-point increase), was 81.8% at three months, and 63.6% at five years (Kayigil, 2012).

Extracorporeal shock wave therapy (low-intensity)

- A systematic review/meta-analysis of 16 randomized controlled trials (n = 1,054) found treatment of erectile dysfunction with shock wave therapy versus placebo (sham treatment or no treatment) improved scores of International Index of Erectile Function ($P < .00001$) and Erectile Hardness Scale ($P = .002$). The impact of age and comorbidities (e.g., hypertension, diabetes, hyperlipidemia, and coronary artery disease) on treatment outcomes and the impact of treatment on other outcome measures such as quality of life require further study (Yao, 2022).
- A systematic review of nine studies (three randomized) revealed post-prostatectomy erectile dysfunction was sometimes more effectively treated by a combination of shock wave therapy and medication versus medication only. Authors agree that the literature is limited for shock wave therapy, and that studies are limited by small sample sizes, high risk of bias, and high heterogeneity (Sighinolfi, 2022).
- A systematic review/meta-analysis of seven studies showed shock wave therapy for erectile dysfunction, compared with vibration without energy transmission, was associated with higher scores using International Index of Erectile Function and Erectile Hardness Scale, both $P < .001$ (Liu, 2022).
- In patients with Peyronie's disease, a Cochrane review found very low to low certainty of evidence supporting any short-term effect of extracorporeal shock wave treatment on patients' self-reported ability to have intercourse, quality of life, or treatment-related adverse effects, or in the degree of penile curvature. No long-term data were available for any outcome (Rosenberg, 2023).

Platelet-rich plasma therapy

A systematic review and meta-analysis of randomized trials of intracavernosal platelet-rich plasma for vasculogenic erectile dysfunction found a mean improvement in International Index of Erectile Function erectile function scores of about 3 points compared with placebo at 6 months, with few and mild adverse events; the authors concluded that platelet-rich plasma is promising but that the evidence base is small, heterogeneous, and insufficient to define its role in routine care (Falcone, 2025).

References

On September 30, 2024, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “erectile dysfunction,” “extracorporeal shock wave therapy,” “penile arterial reconstruction,” and “vacuum erection devices.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Bella AJ, Lee JC, Carrier S, Benard F, Brock GB. 2015 CUA practice guidelines for erectile dysfunction. *Can Urol Assoc J*. 2015;9(1-2):23-29. Doi: 10.5489/cuaj.2699.

Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. *J Urol.* 2018;200(3):633-641. Doi: 10.1016/j.juro.2018.05.004.

Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline. *J Clin Oncol.* 2018;36(5):492-511. Doi: 10.1200/JCO.2017.75.8995.

Doppalapudi SK, Wajswol E, Shukla PA, et al. Endovascular therapy for vasculogenic erectile dysfunction: A systematic review and meta-analysis of arterial and venous therapies. *J Vasc Interv Radiol.* 2019;30(8):1251-1258.e2. Doi: 10.1016/j.jvir.2019.01.024.

European Association of Urology. EAU guidelines on sexual and reproductive health. Published March 2025. <https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2025.pdf>.

Falcone M, et al. Clinical effects and safety outcomes of platelet-rich plasma therapy in patients with vasculogenic erectile dysfunction: a systematic review and meta-analysis. *World J Mens Health.* 2025;[Epub ahead of print]. Doi: 10.5534/wjmh.240310.

Feng D, Liu S, Yang Y, et al. Generating comprehensive comparative evidence on various interventions for penile rehabilitation in patients with erectile dysfunction after radical prostatectomy: A systematic review and network meta-analysis. *Transl Androl Urol.* 2021;10(1):109-124. Doi: 10.21037/tau-20-892.

Ferrini MG, Gonzalez-Cadavid NF, Raifer J, et al. Aging related erectile dysfunction-potential mechanism to halt or delay its onset. *Transl Androl Urol.* 2017;6(1):20-27. Doi: 10.21037/tau.2016.11.18.

Frederick LR, Cakir OO, Arora H, Halfand BT, McVary KT. Undertreatment of erectile dysfunction: Claims analysis of 6.2 million patients. *J Sex Med.* 2014;11(10):2546-2553. Doi: 10.1111/jsm.12647.

Hackett G, Kirby M, Wylie K, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men – 2017. *J Sex Med.* 2018;15(4):430-457. Doi: 10.1016/j.jsxm.2018.01.023.

Kayigil O, Okulu E, Aldemir M, Onen E. Penile revascularization in vasculogenic erectile dysfunction (ED): Long-term follow-up. *BJU Int.* 2012;109(1):109-115. Doi: 10.1111/j.1464-410X.2011.10293.x.

Liu S, Pu J, Li X, Li R, Wang Y, Dong Z. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: A systematic review and meta-analysis. *J Coll Physicians Surg Pak.* 2022;32(9):1181-1186. Doi: 10.29271/jcpsp.2022.09.1181.

Liu JL, et al. Restorative therapies for erectile dysfunction: Position statement from the Sexual Medicine Society of North America (SMSNA). *Sex Med.* 2021;9(3):100343. Doi: 10.1016/j.esxm.2021.100343.

Pirola GM, Naselli A, Maggi M, et al. Vacuum erection device for erectile function rehabilitation after radical prostatectomy: Which is the correct schedule? Results from a systematic, scoping review. *Int J Impot Res.* 2024;36(3):194-200. Doi: 10.1038/s41443-023-00700-w.

Rew KT, Heidelbaugh JJ. Erectile dysfunction. *Am Fam Physician.* 2016;94(10):820-827. American Family Physician website. <https://www.aafp.org/pubs/afp/issues/2016/1115/p820.html>.

Rosenberg JE, Ergun O, Hwang EC, et al. Non-surgical therapies for Peyronie's disease. *Cochrane Database Syst Rev.* 2023;7(7):Cd012206. Doi: 10.1002/14651858.CD012206.pub2.

Shindel AW, Lue TF. Medical and surgical therapy of erectile dysfunction. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. <https://www.ncbi.nlm.nih.gov/books/NBK278925/>. Updated July 17, 2022.

Sighinolfi MC, Eissa A, Bellorofonte C, et al. Low-intensity extracorporeal shockwave therapy for the management of postprostatectomy erectile dysfunction: A systematic review of the literature. *Eur Urol Open Sci.* 2022;43:45-53. Doi: 10.1016/j.euros.2022.07.003.

Theodorus AR, et al. Is the vacuum erectile device suitable for treating erectile dysfunction? A systematic review and meta-analysis exploring the evidence gap. *Arch Ital Urol Androl.* 2025;14328. Doi: 10.4081/aiua.2025.14328. [Epub ahead of print].

Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. *Nat Rev Dis Primers.* 2016;2:16003. Doi: 10.1038/nrdp.2016.3.

Yao H, Wang X, Liu H, et al. Systematic review and meta-analysis of 16 randomized controlled trials of clinical outcomes of low-intensity extracorporeal shock wave therapy in treating erectile dysfunction. *Am J Mens Health.* 2022;16(2):15579883221087532. Doi: 10.1177/15579883221087532.

Policy updates

12/2019: initial review date and clinical policy effective date: 1/2020

12/2020: Policy references updated.

12/2021: Policy references updated.

12/2022: Policy references updated.

12/2023: Policy references updated. Penile implants removed from policy, due to vendor criteria overlap.

12/2024: Policy references updated.

12/2025: Policy references updated.